Kevin Flanagan and Samuel Rines unpack the latest developments in tariffs, tax bills and Treasury markets, and explain why staying grounded in fundamentals is more important than ever.

Christopher Gannatti makes the case that AI is no longer just answering questions—it’s executing goals, marking the rise of “agentic AI” systems.

Moody’s downgrade of U.S. Treasuries to Aa1 aligns with earlier moves by S&P and Fitch and had a relatively muted market impact, with 10-Year yields finishing little changed. Despite credit rating ...

Kevin Flanagan explains why Treasury floating rate notes (FRNs) offer stability without layering on credit risk, making the case for potential solutions like the WisdomTree Floating Rate Treasury Fund ...

Ryan Krystopowicz explains how advisors can become trusted anchors through clarity, emotional intelligence and expert-backed strategies.

There's a tectonic shift unfolding in global finance—subtle in appearance, but profound in implication. The traditional signposts of market anxiety—stocks, bonds, even crypto—are being bypassed in ...

Apple’s iPhone 16 and Samsung’s Galaxy S25 mark a new frontier in AI-driven smartphones, with Apple focusing on privacy-centric, on-device intelligence and Samsung emphasizing interconnected, adaptive ...

Aneeka Gupta and Jeremy Schwartz highlight the WisdomTree Efficient Gold Plus Miners Strategy Fund, which seeks to offer a capital-efficient way to tap into both gold and miners.

Samuel Rines analyzes how early policies in Trump’s second term on energy, infrastructure and trade are reshaping mining and tech.

On a recent episode of the Basis Points podcast, Kevin Flanagan spoke with Morgan Stanley’s Vishwanath Tirupattur to break down the competitive landscape, expected returns and why both private credit ...

With Treasury yields likely to stay elevated, Kevin Flanagan and Sam Rines discuss why investors should prepare for continued volatility and consider a strategic fixed income approach to navigate the ...

After years of underwhelming performance, biotech may finally be ready for a breakthrough in 2025. Chris Gannatti highlights how advancements in gene editing, AI-driven drug discovery and policy ...